Suppr超能文献

肾母细胞瘤复发的预后因素:文献综述

Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature.

作者信息

Groenendijk Alissa, Spreafico Filippo, de Krijger Ronald R, Drost Jarno, Brok Jesper, Perotti Daniela, van Tinteren Harm, Venkatramani Rajkumar, Godziński Jan, Rübe Christian, Geller James I, Graf Norbert, van den Heuvel-Eibrink Marry M, Mavinkurve-Groothuis Annelies M C

机构信息

Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, The Netherlands.

Department of Medical Oncology and Hematology, Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.

出版信息

Cancers (Basel). 2021 Jun 23;13(13):3142. doi: 10.3390/cancers13133142.

Abstract

In high-income countries, the overall survival of children with Wilms tumors (WT) is ~90%. However, overall, 15% of patients experience tumor recurrence. The adverse prognostic factors currently used for risk stratification (advanced stage, high risk histology, and combined loss of heterozygosity at 1p and 16q in chemotherapy-naïve WTs) are present in only one third of these cases, and the significance of these factors is prone to change with advancing knowledge and improved treatment regimens. Therefore, we present a comprehensive, updated overview of the published prognostic variables for WT recurrence, ranging from patient-, tumor- and treatment-related characteristics to geographic and socioeconomic factors. Improved first-line treatment regimens based on clinicopathological characteristics and advancing knowledge on copy number variations unveil the importance of further investigating the significance of biological markers for WT recurrence in international collaborations.

摘要

在高收入国家,肾母细胞瘤(WT)患儿的总体生存率约为90%。然而,总体而言,15%的患者会出现肿瘤复发。目前用于风险分层的不良预后因素(晚期、高危组织学以及初治WT中1p和16q杂合性联合缺失)仅存在于三分之一的此类病例中,并且随着知识的进步和治疗方案的改进,这些因素的意义易于改变。因此,我们提供了一份全面、更新的关于WT复发的已发表预后变量概述,范围涵盖从患者、肿瘤和治疗相关特征到地理和社会经济因素。基于临床病理特征的改良一线治疗方案以及对拷贝数变异认识的不断深入,揭示了在国际合作中进一步研究WT复发生物学标志物意义的重要性。

相似文献

4
Gain of 1q is a marker of poor prognosis in Wilms' tumors.1q 增益是肾母细胞瘤预后不良的标志物。
Genes Chromosomes Cancer. 2013 Nov;52(11):1065-74. doi: 10.1002/gcc.22101. Epub 2013 Sep 4.

引用本文的文献

本文引用的文献

2
TRIM28 variants and Wilms' tumour predisposition.TRIM28 变异与肾母细胞瘤易感性。
J Pathol. 2021 Jul;254(4):494-504. doi: 10.1002/path.5639. Epub 2021 Mar 15.
3
New approaches to risk stratification for Wilms tumor.新的肾母细胞瘤风险分层方法。
Curr Opin Pediatr. 2021 Feb 1;33(1):40-48. doi: 10.1097/MOP.0000000000000988. Epub 2020 Dec 29.
9
Less may be more for stage I epithelial Wilms tumors.对于I期上皮性肾母细胞瘤,少或许就是多。
Cancer. 2020 Jun 15;126(12):2762-2764. doi: 10.1002/cncr.32854. Epub 2020 Apr 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验